Clinical Trial Categories
Myelofribrosis Trials
Trial ID 20177 STAR
NCT04472598clinicaltrials.gov ID
USOR ID: 20177
Phase III
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Navitoclax in Combination with Ruxolitinib versus Ruxolitinib in Subjects with Myelofibrosis (TRANSFORM-1)
